

UNIVERSITA' DEGLI STUDI DI MILANO BICOCCA  
DOTTORATO DI RICERCA IN STATISTICA  
XXIII CICLO

TESI

On the Proof of Efficacy of Functional Foods:  
Design Considerations

Relatore:  
Prof. Dario Gregori

Candidata:  
Dott.ssa Ileana Baldi

2011

# Contents

<b>1</b>	<b>Introduction</b>	<b>1</b>
<b>2</b>	<b>Functional Foods</b>	<b>3</b>
2.1	Regulation and health claims for functional foods . . . . .	4
2.2	Endpoint identification . . . . .	8
2.3	Study design . . . . .	10
<b>3</b>	<b>Surrogate Endpoints</b>	<b>11</b>
3.1	Validation on individual data . . . . .	12
3.2	Validation on summary statistics: a meta-analysis perspective	18
<b>4</b>	<b>Evidence-based research</b>	<b>22</b>
4.1	Evidence-based nutrition . . . . .	25
4.2	Continuous data . . . . .	25
4.3	Validation of a prognostic model . . . . .	28
<b>5</b>	<b>Surrogate Endpoint for Cardiovascular Risk Reduction: a case-study</b>	<b>30</b>
5.1	Methods . . . . .	31
5.2	Results . . . . .	34
5.3	Discussion . . . . .	40
<b>6</b>	<b>Conclusions</b>	<b>41</b>
<b>7</b>	<b>Appendix</b>	<b>43</b>
	<b>References</b>	<b>59</b>

# 1 Introduction

At the turn of the 21st century, modern society faces new challenges, from exponentially growing costs of health care, increase in life expectancy, improved scientific knowledge, and development of new technologies to major changes in lifestyles. Nutrition has to adapt to these new challenges by developing new concepts. Optimal nutrition is one of these, aimed at maximizing physiologic functions of each individual to ensure both maximum well-being and health, and, at the same time, confer a minimum risk of disease throughout the lifespan. Although the connection between diet and health has long been recognized, currently we are learning more about how global lifestyle and dietary approaches can prevent disease. Knowledge of the role of physiologically active food components, from plant, animal, and microbial food sources, has changed the role of diet in health. Nutritional issues have shown the relationship between diet and ageing, obesity, heart disease, and cancer [1].

Many interventions have been proposed through policy makers, most of them regarding the deprivation of normal components (salt, sugar or fat) in order to provide healthier products. A different proposal has, as principal category of interest, functional food, with the aim of following usual dietary pattern, adding functionality to the common nutrients.

By definition, functional foods benefit human health beyond the effect of nutrients alone. Functional foods have evolved as food and nutrition science has advanced beyond the treatment of deficiency syndromes to reduction of disease risk and health promotion and, owing to their ability to confer health and physiological benefits, are increasing in popularity.

The aims of functional food science, as summarized in [2], are, to identify beneficial interactions between a functional food component and one or more target functions in the body and to obtain evidence for the underlying mechanisms; to identify and validate markers for these functions and their modulation by food components; to assess the safety of the amount of food

or its components needed for functionality; to formulate hypotheses to be tested in human intervention studies that aim to show that the relevant intake of specified food components is associated with improvement in one or more target functions, either directly, or in terms of a valid marker of an improved state of health and well-being and/or a reduced risk of a disease. A sound scientific evidence from such studies, both observational studies and randomized clinical trials (RCTs), is required to substantiate claims on a functional food.

A direct measurement of the effect a food on health and well-being and/or reduction of disease risk is often not possible. Therefore, one key, but difficult, step in the development of functional foods is the identification and validation of relevant markers that can predict potential benefits or risks relating to certain health conditions.

The second key step, once the surrogate has been identified and validated, is to frame the proof within a study design that is able to link the inference on the surrogate with the inference that would be made on the true endpoint, had it been observed.

The aim of this work is to address this research question, by assuming that there is a known relationship between the surrogate and the true endpoint explored during the surrogacy assessment. Statistical inference on the true (unobserved) endpoint is derived on the basis of its predicted values.

After a brief review of the concept of statistical surrogacy, we illustrate this approach through a motivating example from literature on surrogates for cardiovascular risk prevention, integrated with simulated scenarios.

## 2 Functional Foods

The term “functional food” was introduced for the first time in the middle of 1980s in Japan when, faced with escalating health care costs, the Ministry of Health and Welfare initiated a regulatory system to approve certain foods with documented health benefits in hopes of improving the health of the nation’s aging population.

Several definitions of functional food exist. These include, the working definition given by The European Commission Concerted Action on Functional Food Science in Europe, co-ordinated by The International Life Sciences Institute (ILSI- Europe) [2] that regards a food as functional “ if it is satisfactorily demonstrated to affect beneficially one or more target functions in the body, beyond adequate nutritional effects, in a way that is relevant to either an improved state of health and well-being and/or reduction of risk of disease”.

Functional foods may be broadly grouped into three categories: conventional food containing naturally occurring bioactive substance, food to which a component has been added or from which a component has been removed by technological or biotechnological means, and food in which a component has been modified in nature and/or bioavailability. Examples of these are shown in Table 1.

Functional foods are not medicines. In fact, their purpose is to restore or enhance normal function in order to optimize health, well-being and performance, and to reduce risk factors for disease and not to treat or prevent diseases, or to heighten physiological performance outside the normal range. Functional foods are intended to be consumed as part of a normal diet and they take the form of foods whereas medicines are intended to be taken as part of a controlled regimen in tablets or pills which can be administered in precise doses. Ultimately, the manufacture and marketing of medicines is subject to different regulatory controls than those that apply to the manufacture and marketing of foods.

Functional food	Food Component	Potential health benefit
Spinach	Calcium	may reduce the risk of osteoporosis
Processed tomato products	Lycopene	may contribute to maintenance of prostate health
Table spreads (butter or margarine alternatives) fortified with stanol and/or sterol esters	Stanol/Sterol esters	may reduce the risk of coronary heart disease (CHD)
Soy-based products	Soy protein	may reduce the risk of coronary heart disease (CHD)
Wheat bran	Insoluble Fiber	may contribute to maintenance of a healthy digestive tract may reduce the risk of some types of cancer

Table 1. Functional Foods Component Chart 2009. Adapted from International Food Information Council (IFIC) Foundation (<http://www.ific.org/nutrition/functional/index.cfm>).

## 2.1 Regulation and health claims for functional foods

Several mid- and long-term developments in society, as well as socio-demographic trends are in favor of functional food, so that it can be assumed that functional food represents a sustainable category in the food market. Moreover, it is beyond doubt that persuading people to make healthier food choices would provide substantial (public) health effects, therefore it is a common economic and public interest.

Foods are typically chosen for their good taste, convenience and price with health being only one reason among many and functional foods are not exceptions in this. Consumers can only be expected to substitute conventional

with functional foods if these latter are perceived as comparatively healthy and the promised health benefits are regarded as relevant. As consumers become more health conscious, the demand and market value for health-promoting foods and food components is expected to grow. Before the full market potential can be realized, however, consumers need to be assured of the safety and efficacy of functional foods. These are two key aspects in a potential food evaluation.

As in most other regulations, with Japan and its “foods for specified health use, FOSHU” as a notable exception, in the USA and in Europe there is no regulatory policy specific to functional foods. Rather they are regulated under the same framework as conventional food.

As the relationship between nutrition and health gains public acceptance and as the market for functional foods grows, the question of how to communicate the specific advantages of such foods becomes increasingly important. The fundamental principle defining food allegations or claims is that they must be scientifically proved, not ambiguous and clear to the consumer. However, different definitions exist, depending on the country and its policy. In Europe, the Regulation 1924/2006/EC on nutrition and health claims was agreed in December 2006 and came into force in 2007 [3]. The Regulation 1924/2006/EC provides the definitions of nutrition claim (any claim that states, suggests or implies that a food has particular beneficial nutritional properties), health claim (any claim that states, suggests or implies that a relationship exists between a food category, a food or one of its constituents and health) and reduction of disease risk claim (any health claim that states, suggests or implies that the consumption of a food category, a food or one of its constituents significantly reduces the risk of a human disease) [4]. Health claims are divided into Article 14 and Article 13 claims depending on whether they refer or not to either the reduction of disease risk or to children’s development and health, respectively.

The assessment of the scientific evidence to support health claims is the responsibility of the European Food Safety Authority (EFSA). In USA the responsibility for ensuring the validity of these claims rests with the manufacturer, Food and Drug Administration (FDA), or, in the case of advertising,

with the Federal Trade Commission. Claims that can be used on food and dietary supplement labels fall into three categories: health claims (imply a relationship between dietary components and reducing risk of a disease or health condition), nutrient content claims (characterize the level of a nutrient or a dietary substance in a food), and structure/function claims (describe the role of substances that affect normal functioning of the body).

The ways by which FDA exercises its oversight in determining which health claims may be used on a label or in labeling for a food or dietary supplement are the 1990 Nutrition Labeling and Education Act, the 1997 Food and Drug Administration Modernization Act and the 2003 FDA Consumer Health Information for Better Nutrition Initiative.

There are generally two types of labeling claims that embrace but are not restricted to functional foods: structure/function claims (similar to Article 13 health claims in Europe) and health claims (similar to disease-risk reduction claims in Europe). No statements about treating a disease should be made, otherwise a functional food would be a drug [5].

Examples of strong scientific evidence of clinical efficacy is for functional foods that satisfied rich in fiber (oat bran or psyllium), which are associated with several health effects. The major direct effects include improved bowel function as treatment of irritable bowel syndrome, increased mineral absorption, altered lipid metabolism as reduced incidence of coronary heart disease [1]. Examples of approved health claims by FDA are given in Table 2.

Several guidelines have been developed, for example, those in the USA, Canada, Australia/New Zealand and the UK give detailed guidance on the nature of scientific evidence required and suggest how it should be evaluated. In Europe, the project “Process for the Assessment of Scientific Support for Claims on Foods” (PASSCLAIM) had as its main objective the production of a generic tool to assess the scientific support for health-related claims for foods and food components [6]. The future of functional foods will undoubtedly involve a continuation of the labeling and safety debates.



Approved Health Claims	Requirement for the food	Model claim
Soluble Fiber (SF) from certain foods and risk of CHD	<p>Low saturated fat</p> <p>Low cholesterol</p> <p>Low fat</p> <p>Whole oat or barley foods* &gt;0.75 g SF/RACC</p> <p>Oatrim &gt;0.75 g <math>\beta</math>-glucan SF/RACC</p> <p>Psyllium husk &gt;1.7 g SF/RACC</p> <p>The amount of SF/RACC must be declared in nutrition label.</p>	<p>SF from foods such as [name of SF source, and, if desired, name of food product], as part of a diet low in saturated fat and cholesterol, may reduce the risk of heart disease.</p> <p>A serving of [name of food product] supplies . g of the [necessary daily dietary intake for the benefit] SF from [name of SF source] necessary per day to have this effect.</p>
Soy-protein and risk of CHD	<p>Low saturated fat</p> <p>Low cholesterol</p> <p>Low fat**</p> <p><math>\geq 6.25</math> g soy protein/RACC</p>	<p>25 g of soy protein a day, as part of a diet low in saturated fat and cholesterol, may reduce the risk of heart disease. A serving of [name of food] supplies . g of soy protein.</p>

Table 2. Some approved health claim by FDA (CHD: Coronary Heart Disease; RACC: Reference Amount Customarily Consumed; \*include oat bran and/or rolled oats and/or whole oat flour and/or whole grain barley or dry milled barley; \*\*except that foods made from whole soybeans that contain no fat in addition). Adapted from: <http://www.fda.gov/Food/GuidanceComplianceRegulatoryInformation/GuidanceDocuments/FoodLabelingNutrition/FoodLabelingGuide/ucm064919.htm>.

## 2.2 Endpoint identification

A direct measurement of the effect a food on health and well-being and/or reduction of disease risk is often not possible. Therefore, one key, but difficult, step in the development of functional foods is the identification and validation of relevant markers that can predict potential benefits or risks relating to certain health conditions.

Depending on the conditions of interest different kinds of markers can be chosen to measure efficacy, or a certain risk (to evaluate safety properties), or a certain function (to investigate the mechanistic function of a nutritional compound), or compliance of the study participants. In addition to these, also markers for an early prediction of improvement and special markers for demonstration of a claimed effect (validated markers to demonstrate a claimed effect of a substance) were suggested [6,7]. Measurements made early on carefully chosen markers can be used to make inferences about effects on final endpoints that would only otherwise be accessible through long-term observation.

In general, all markers should be feasible, valid, reproducible, sensitive and specific. Criteria for markers are given in [2]. It is recognized that the use of markers reduces costs, sample size, and completion of a study [8].

In the context of the cardiovascular system, cardiovascular diseases (CVD) are a group of degenerative diseases of the heart and blood circulatory system and include coronary heart disease (CHD), peripheral artery disease and stroke. Known risk factors associated with its development include high blood pressure, inflammation, inappropriate blood lipoprotein levels, insulin resistance and control of blood clot formation.

Table 3 (adapted from [6]) provides examples of potential markers for key target functions related to the cardiovascular system and candidate food components for modulation of these functions. For example, if CVD risk were the principal research question of a study on a functional food component, the use of measures of blood cholesterol, a validated surrogate endpoint of CVD, would save costs and time since the study observation period would not have to extend until the CVD develops, which can require years or decades.

Target functions	Potential marker	Candidate food component
Lipoprotein Homeostasis	Lipoprotein profile:	SFA(↓)
	LDL-cholesterol	MUFA, PUFA
	HDL-cholesterol	Plant sterol and stanol esters
	Triacylglycerol	Soluble fiber
		Tocotrienols
		Soy protein
		Fat replacers
		$\beta$ -glucan
		trans-fatty acids (↓)
Endothelial and arterial integrity Thrombogenic potential	Growth factors	Certain antioxidants
	Adhesion molecules	Vitamin E
	Cytokines	n-3 PUFA
	Platelet function	n-3 PUFA
	Clotting function	Linoleic acid
		Certain antioxidants
Control of hypertension	Systolic and diastolic blood pressure	Total energy intake (↓)
		Sodium chloride (↓)
		n-3 PUFA
Control of homocysteine	Plasma homocysteine levels	Folic acid
		Vitamin B6
		Vitamin B12

Table 3. Examples of potential markers for key target functions related to the cardiovascular system and candidate food components for modulation of these functions. (LDL=low-density lipoprotein; HDL=high-density lipoprotein; (↓)=reduced intake; SFA=saturated fatty acids; MUFA=monounsaturated fatty acids; n-3 PUFA=n-3 series of long-chain fatty acids).

## 2.3 Study design

Functional food research encompasses several types of study designs, including observational studies and randomised clinical trials (RCTs).

The most common types of observational studies are prospective cohort studies, case-control studies, and cross-sectional studies, the latter two being retrospective. In a RCT, as in any intervention study, the investigator controls exposure of study subjects to the test substance; whereas in an observational study, the investigator observes, but does not control the exposure.

Whether RCT, which has become the gold standard for establishing the efficacy of pharmacologic agents, should be at the top of the pyramid also in nutritional research, remains a controversial issue.

Some authors [9] argue that RCT is poorly suited to the evaluation of nutritional effects for several reasons. First, the selection of an appropriate control dietary intervention. Second, the so-called threshold behavior (i.e. some physiologic measure improves as intake rises up to a level of sufficiency, above which higher intakes produce no additional benefit). Third, the presence of multiple co-primary endpoints related to beneficial effects on multiple tissues and organ systems, rather than a focus on a primary outcome measure, which is favored by RCTs. Moreover, RCT can be conclusive in certain cases but it may not be possible to carry out such a study type for all targets or all situations.

In addition, there may be ethical reasons why RCTs are not applicable for certain nutritional interventions. It is also of note that some of the “most conclusive” evidence in food functionality (e.g. for vitamins) is coming from observational data and associations, rather than RCTs which are required for evidence that is only being established.

Conversely, other authors [8] state that RCT represents the definitive assessment tool for establishing causal relationship between food components and health and disease risk. Therefore, well designed RCTs serve as a definitive benchmark for functional food-based claims. Undoubtedly, further research is needed to redesign RCT methodology that would adequately serve the need to demonstrate the health effects of foods.

### 3 Surrogate Endpoints

Markers and surrogate endpoints have an increasingly important role in both clinical and nutritional research. However, the challenges that must be overcome in their adoption are many, and range from discovery and verification through to statistical validation, successful use in nutritional epidemiology studies and, lastly, routine use.

From a statistical standpoint, according to the definitions given in [10] that best pertain to functional food research, we refer to a validated marker as one that has been demonstrated by robust statistical methods to forecast the likely response to a dietary intervention (predictive biomarker) or to be able to replace a clinical endpoint to assess the effect of a relevant intake of specified food components (surrogate endpoint). Despite the potential of surrogate endpoints, there is no widely accepted agreement about what constitutes a valid surrogate endpoint. In early discussions about surrogate endpoints, a common misconception was that it was sufficient for this endpoint to be prognostic for the clinical endpoint to establish surrogacy.

Different approaches have been taken by researchers to quantify the treatment effect on the clinical outcome explained by the surrogate endpoint: 1) analysis based on individual patient data (IPD), and 2) meta-regression based on summary statistics from published literature.

It is widely recognized that by accessing original data, one can enhance comparability among studies with respect to inclusion/exclusion criteria, definitions of variables, adjustments of covariates, estimation of parameters by the same statistical method and perform model building and diagnostics [11]. Providing summary statistics is logistically simpler than transferring original data. Moreover, protection of human subjects and other study policies often prohibit investigators from releasing IPD.

### 3.1 Validation on individual data

The mathematical construct to a problem that had traditionally been carried out by intuition, was given by Prentice [12] in his landmark paper. Prentice proposed a formal definition of a surrogate endpoint and suggested operational criteria for its validation in the case of a single trial and single surrogate.

Define  $T$  and  $S$  to be the random variables that denote the true and surrogate endpoints, respectively,  $Z$  to be a binary indicator variable for treatment and  $j$  the index for the  $j$ -th subject enrolled in the study. The endpoints  $T$  and  $S$  can be discrete or continuous, possibly censored, random variables. Prentice's definition can be written as  $f(S|Z) = f(S) \iff f(T|Z) = f(T)$ , where  $f(\cdot)$  denotes the probability distribution of random variable and  $f(\cdot|\cdot)$  denotes the conditional probability distribution. Note that this definition involves the triplet  $(T, S, Z)$ , hence the endpoint  $S$  is a surrogate for  $T$  only with respect to the effect of some specific treatment  $Z$ , except if  $S$  were a perfect surrogate for  $T$ , i.e., if  $S$  and  $T$  were the same endpoint up to a deterministic transformation.

According to the definition, a surrogate endpoint is a random variable for which a test for the null hypothesis of no treatment effect is also a valid test for the corresponding null hypothesis for the true endpoint.

Prentice proposed four operational criteria to check if a triplet  $(T, S, Z)$  fulfills the definition. Symbolically, they can be written as follows:

$$\begin{aligned} f(S|Z) &\neq f(S) \\ f(T|Z) &\neq f(T) \\ f(T|S) &\neq f(T) \\ f(T|S, Z) &= f(T|S) \end{aligned}$$

In words, the first criterion states that the surrogate endpoint is associated with treatment. The second states that the true endpoint is associated with treatment. The third is that the surrogate and the true endpoints are associated. The last criterion states that, given the surrogate endpoint, treat-

ment and the true endpoint are independent. Popularly, the last criterion is referred to as the Prentice criterion.

To exemplify as in [13], we consider a formulation for joint modeling of the endpoints through a bivariate model where the effect of the treatment on the surrogate is modeled by:

$$S_j = \mu_S + \alpha Z_j + \epsilon_{Sj} \quad (1)$$

and the effect of the treatment on the true endpoint is modeled by:

$$T_j = \mu_T + \beta Z_j + \epsilon_{Tj} \quad (2)$$

and the error terms have a joint zero-mean Normal distribution with variance-covariance matrix  $\Sigma = \begin{pmatrix} \sigma_{SS} & \sigma_{ST} \\ & \sigma_{TT} \end{pmatrix}$ .

The first two operational criteria require testing the significance of parameters  $\alpha$  and  $\beta$ . The third criterion can be verified using the test for parameter  $\gamma$  in the model describing the relationship between  $S$  and  $T$ :

$$T_j = \mu + \gamma S_j + \epsilon_j \quad (3)$$

The so-called Prentice criterion is verified through the conditional distribution of  $T$  given  $Z$  and  $S$ :

$$T_j = \tilde{\mu}_T + \beta_S Z_j + \gamma_Z S_j + \tilde{\epsilon}_{Tj} \quad (4)$$

where  $\beta_S = \beta - \sigma_{ST}\sigma_{SS}^{-1}\alpha$  and  $\gamma_Z = \sigma_{ST}\sigma_{SS}^{-1}$  and it requires that  $\beta_S$  be non-significant. This raises a conceptual difficulty.

Freedman, Graubard, and Schatzkin [14] argued that the last Prentice criterion might be adequate to reject a poor surrogate endpoint (if a test for treatment effect upon the true endpoint remains statistically significant after adjustment for the surrogate), but it is inadequate to validate a good surrogate endpoint, since failing to reject the null hypothesis may be due merely to insufficient power. Therefore, they proposed to use the proportion of treatment effect explained by the surrogate endpoint as a measure of the validity of a potential surrogate. A high proportion would indicate that a

surrogate is useful.

Let  $PE(T, S, Z)$  be for the proportion of the effect of  $Z$  on  $T$  which can be explained by  $S$ . An estimate of the explained proportion is

$$PE(T, S, Z) = (\beta - \beta_S) / \beta \quad (5)$$

where  $\beta$  and  $\beta_S$  are the estimates of the effect of  $Z$  on  $T$ , respectively, without and with adjustment for  $S$ .  $PE$  being the ratio of two parameters, its confidence limits can be calculated using Fieller's theorem or the delta method [15].

Several authors have pointed towards drawbacks of the measure. For instance, Buyse and Molenberghs [16] have shown that the proportion of treatment effect explained by the surrogate is not truly a proportion, as it can fall out of the  $[0, 1]$  interval. As an alternative, Buyse and Molenberghs [16] proposed to replace the proportion of treatment effect explained by the surrogate by another set of surrogacy criteria closely related to it: the relative effect ( $RE$ ) and the adjusted association ( $AA$ ). The former, defined at the population level, is the ratio of the overall treatment effect on the true endpoint over that on the surrogate endpoint ( $\beta/\alpha$ , under the current notation). The second one is the individual-level association between both endpoints, after accounting for the effect of treatment.

Intuitively,  $RE$  is a conversion factor between the treatment effect on the surrogate to that on the primary endpoint. If the multiplicative relation could be assumed, and if  $RE$  were known exactly, it could be used to predict the effect of  $Z$  on  $T$  based on an observed effect of  $Z$  on  $S$ . In practice,  $RE$  will have to be estimated, and the precision of the estimation will be relevant for the precision of the prediction.

Generically,  $AA = corr(T|Z, S|Z)$  is the correlation between the true and surrogate endpoint after adjusting for the treatment effect. In the previous example of normally distributed endpoints,  $AA = \sigma_{ST} / \sqrt{\sigma_{SS}\sigma_{TT}}$ . It follows that, if  $AA = 1$ , one could call the surrogate "perfect at the individual level", as the knowledge of  $S$  and  $Z$  would allow for an exact prediction of the value of  $T$  for an individual subject. In a general situation, it is then important to



judge whether the correlation is considered high enough for the surrogate to be trustworthy.

Another line of research has been in the setting corresponding to a multi-center trial or a meta-analysis of trials [17]. Thus, the current notation will be supplemented using index  $i$  for the  $i$ -th center or trial. A natural formulation for joint modeling of the endpoints is through a bivariate mixed model:

$$\begin{aligned} S_j &= \mu_S + \alpha Z_{ij} + m_{S_i} + a_i Z_{ij} + \epsilon_{S_{ij}} \\ T_j &= \mu_T + \beta Z_{ij} + m_{T_i} + b_i Z_{ij} + \epsilon_{T_{ij}} \end{aligned} \quad (6)$$

where  $\mu_S$  and  $\mu_T$  are fixed intercepts,  $\alpha$  and  $\beta$  are the fixed effects of  $Z$  on the endpoints,  $m_{S_i}$  and  $m_{T_i}$  are random intercepts and,  $a_i$  and  $b_i$  the random effects of  $Z$  on the endpoints in the  $i$ -th trial. The correlated error terms  $\epsilon_{S_{ij}}$  and  $\epsilon_{T_{ij}}$  are assumed to be zero-mean normally distributed with variance-covariance matrix  $\Sigma = \begin{pmatrix} \sigma_{SS} & \sigma_{ST} \\ & \sigma_{TT} \end{pmatrix}$  and the vector of random effects is assumed to be zero-mean normally distributed with variance-covariance matrix:

$$D = \begin{pmatrix} d_{SS} & d_{ST} & d_{SA} & d_{SB} \\ & d_{TT} & d_{TA} & d_{TB} \\ & & d_{AA} & d_{AB} \\ & & & d_{BB} \end{pmatrix}$$

We denote with  $\theta$  the vector of fixed-effects parameters and variance components.

The association between both endpoints after adjustment for the treatment effect is captured by the squared correlation between  $S$  and  $T$  after adjustment for both the trial effects and the treatment effect:

$$R_{between-trial}^2 = \sigma_{ST}^2 / \sigma_{SS}\sigma_{TT} \quad (7)$$

This aspect of surrogacy is generally referred to as individual-level surrogacy, which means that for individual patients, the marker or surrogate outcome must correlate well with the final endpoint of interest. It generalizes  $AA$  to the case of several trials.

A measure to assess the quality of the surrogate at the trial level is the coefficient of determination:

$$R_{within-trial}^2 = \frac{\begin{pmatrix} d_{SB} & d_{AB} \end{pmatrix} \begin{pmatrix} d_{SS} & d_{SA} \\ d_{SA} & d_{AA} \end{pmatrix}^{-1} \begin{pmatrix} d_{SB} \\ d_{AB} \end{pmatrix}}{d_{BB}} \quad (8)$$

This coefficient is unit-less and ranges in the unit interval if the corresponding variance-covariance matrix is positive definite. This aspect of surrogacy is named trial-level surrogacy since it must be demonstrated for a group of patients in a trial.

With respect to trial-level surrogacy, the concept of a “surrogate threshold effect” (*STE*) was recently introduced [13]. *STE* is defined as the minimum treatment effect on the surrogate required to predict a nonzero treatment effect on the clinical endpoint in a future trial. If the *STE* is small (ie, realistically achievable by future treatments) then the surrogate may be of potential interest. If, in contrast, the *STE* is large then the surrogate is unlikely to be of practical value. Finally, if the *STE* cannot be estimated at all then we have no statistical basis to make claims of surrogacy.

We recall the previous example where  $S$  and  $T$  are jointly normally distributed and assume that data on the surrogate endpoint from a new trial ( $i = 0$ ) are available. Under the current notation, by fitting

$$S_{0j} = \mu_{S0} + \alpha Z_{0j} + \epsilon_{S0j} \quad (9)$$

we get estimates for  $m_{S0}$  and  $a_0$ ,  $\hat{m}_{S0} = \hat{\mu}_{S0} - \hat{\mu}_S$  and  $\hat{a}_0 = \hat{\alpha}_0 - \hat{\alpha}$ , respectively. Under the assumption that the treatment effect on the surrogate in a new trial,  $\beta + b_0$ , is predicted independently of  $\mu_{S0}$ , the conditional mean and variance of  $\beta + b_0$  can be respectively written as:

$$\begin{aligned} E(\beta + b_0 | \alpha_0, \theta) &= \beta + d_{AB}/d_{AA}(\alpha_0 - \alpha) \\ Var(\beta + b_0 | \alpha_0, \theta) &= d_{BB} - d_{AB}^2/d_{AA} = d_{BB}(1 - R_{within-trial}^2) \end{aligned} \quad (10)$$

If we assume that  $d_{AB} > 0$  and that positive values of  $\alpha_i$  indicate a positive treatment effect in trial  $i$ , the  $(1-\gamma)100\%$  prediction interval of  $\beta + b_0$

can be expressed as:

$$E(\beta + b_0|\alpha_0, \theta) \pm z_{1-\gamma/2}\sqrt{Var(\beta + b_0|\alpha_0, \theta)} \quad (11)$$

where  $z_{1-\gamma/2}$  is the quantile  $1 - \gamma/2$  of the standard normal distribution. The lower and upper limit of this interval,  $l(\alpha_0)$  and  $u(\alpha_0)$ , respectively, are functions of  $\alpha_0$ . The value of  $\alpha_0$  such that  $l(\alpha_0) = 0$  is the *STE*.

Many advocate that results from studies where only the surrogate is observed should never be considered definitive. As a consequence, several methods have been proposed for augmented surrogate endpoints. Such methods assume that there is a sample where complete information on the surrogate, primary endpoint and covariates are observed, and a sample where the primary endpoint cannot be observed and only information on the surrogate and the covariates are available. This is data coarsening [18], a generalized concept of missingness. According to a recent review [19], these methods encompass likelihood-based approaches assuming a full parametric model for the joint distribution for  $(T, S)$  and requiring few assumption on coarsening; non-likelihood approaches where the lack of a full specification on the joint distribution for  $(T, S)$  is compensated by stronger assumptions on the coarsening mechanisms; and non-likelihood based methods making just some assumptions on the joint distribution of  $(T, S)$ . Although there is not a single overall best method, in general the gains in using augmented surrogate endpoint approaches is high only if  $S$  is a good correlate for  $T$  and if the amount of missing assessments of the primary endpoint is moderate or high [19]. The mechanism that governs this missingness (i.e. at random, completely at random, ...) is crucial in all the methods.

More recent research has been utilizing ideas of causal inference to the assessment of surrogacy. The first approach was described by Robins and Greenland [20]. In their work, the surrogate endpoint is an intermediate variable measured after the baseline covariates and before the outcome. This variable is manipulable and can affect the outcome independently of the treatment. From the causal viewpoint towards surrogacy, it is crucial to be able to formulate appropriate causal pathways in considering the effects

of a treatment on a surrogate and the true endpoint. This underscores the necessity in enhancing understanding of the biological role of surrogates on mechanisms by which food components positively affect health. Figure 1 shows a valid pathway for a surrogate endpoint.




Figure1: Paradigm for valid surrogate endpoint

Lassere [21] has proposed a formal schema for numerically assessing the strength of the relationship between  $S$  and  $T$ , based on a weighted evaluation of biological, epidemiological, statistical, clinical trial and risk-benefit evidence.

### 3.2 Validation on summary statistics: a meta-analysis perspective

The basic situation in meta-analysis is that we are dealing with  $n$  studies in which a parameter of interest is estimated. In a meta-analysis of clinical trials the parameter is a measure of the difference in efficacy between the two treatment arms. Combination of estimates is usually achieved using one of two assumptions, yielding a fixed-effect or random-effects meta-analysis (see [22] for a review).

Methods based on the mathematical assumption that a single common (or 'fixed') effect underlies every study in the meta-analysis are referred to as fixed effect meta-analyses. Methods that assume individual studies to estimate different true treatment effects are referred to as random-effect meta-analyses. Another term for such between-study variation is heterogeneity.

Prior to performing a meta-analysis, it is customary to test for heterogeneity. In general,  $Q$  test [23] is computed by summing the squared deviations of each study's effect estimate from the combined effect estimate, weighting the contribution of each study by its inverse variance. It is well recognized that the power of this test is low and that it may be preferable to know the extent of true heterogeneity. The  $I^2$  statistic [24] accomplishes this task by describing the percentage of variation in effect estimates that is due to heterogeneity.

There is a great deal of debate about whether it is better to use a fixed or random effect meta-analysis. The debate is not about whether the underlying assumption of a fixed effect is likely but more about which is the better trade off, stable robust techniques with an unlikely underlying assumption or less stable techniques based on a somewhat more likely assumption. The random-effects method has long been associated with problems due to the poor estimation of among-study variance when there is little information.

In contrast to simple meta-analysis, combinations of meta-analytic principles with regression ideas (of predicting study effects using study-level covariates) have been developed, namely meta-regressions. Meta-regression aims to relate the size of effect to one or more study-level characteristics. It is appropriate to use meta-regression to explore sources of heterogeneity even if an initial overall  $Q$  test for heterogeneity is non-significant. Some would argue that, given the diversity of trials in any meta-analysis, that heterogeneity must exist and whether we happen to be able to detect it or not is irrelevant.

The outcome (or dependent) variable in a meta-regression analysis is usually a summary statistic, for example the observed log odds ratio from each trial. The estimated variance of this summary statistic is assumed to be the true variance, an assumption that is questionable when trials are small.

Under a fixed-effect meta-regression model, we may assume that the observed log odds ratio ( $y_i$ ) are independently normally distributed as:

$$y_i \sim N(\phi + \gamma x_i, \nu_i^2) \tag{12}$$

where  $\nu_i^2$  is the variance of the log odds ratio and  $x_i$  denotes the covariate

value in the  $i$ -th trial.

Maximum Likelihood (ML) estimates may be obtained by ordinary least squares with weights  $w_i = 1/\nu_i^2$ . This method is known as Weighted Least Squares (WLS) regression. The ratio between Pearson goodness-of-fit  $\chi^2$  and the model degrees of freedom, provides an estimate of the overdispersion parameter. This give indications of residual heterogeneity and can be thought as a multiplicative factor for  $\nu_i^2$ .

Heterogeneity can be incorporated in a meta-regression model by adding to (12) a between-study variance component ( $\tau^2$ ) that represents the excess variation in observed effects over that expected from within-study variation:

$$y_i \sim N(\phi + \gamma x_i, \nu_i^2 + \tau^2) \quad (13)$$

ML estimates may be obtained by ordinary least squares with weights  $w_i = 1/(\nu_i^2 + \tau^2)$ .  $\tau^2$  must be explicitly estimated in order to undertake the weighted regression and this is somewhat problematic. Different estimates have been advocated such as restricted ML (REML) estimate and the empirical Bayes estimate. Methods which use the binomial model for observed proportions rather than assuming normality of the log-odds ratios, though preferable in principle, often give similar results in practice [25].

When the independent variable in a meta-regression represents a dose or exposure level and summarized data are reported as a series of dose-specific odds ratios, with one category serving as the common referent group, the WLS method to trend estimation is no longer suitable. Greenland and Longnecker [26] suggested the use of Generalized Least Squares (GLS) to allow for the correlation between log odds ratios. This method is then incorporated in the estimation of fixed and random-effects meta-regression models for the analysis of multiple studies.

The correlation between  $y_{jk}$  and  $y_{jl}$ , the  $k$ -th and  $l$ -th log odds ratio in the  $i$ -th study, is  $r_{i,kl} = v_{i0}/\sqrt{(v_{ik}v_{il})}$ , where for  $i \neq k$ ,  $v_{i0} = 1/C_{i0} + 1/D_{i0}$  and  $v_{ik} = 1/C_{i0} + 1/D_{i0} + 1/C_{ik} + 1/D_{ik}$ , being  $(C_{i0}; D_{i0})$  and  $(C_{ik}; D_{ik})$  the numbers of cases and controls, respectively, for the unexposed group ( $x = 0$ ) and the exposed group with assigned dose  $x_{ik}$ . Assuming that the log odds

ratio in the unexposed group (reference category) is zero, no intercept models are used.

Adaptations to this method for trend estimation that allow for both correlation between log odds ratios and arbitrarily aggregated dose-levels have been implemented [27].

The criteria for surrogacy given in the previous section, except those defined at individual-level, may be assessed on summary statistics via meta-regression although several limitations of this approach must be recognized. The associations derived from meta-regressions are observational, although the original studies may be randomized trials, and have a weaker interpretation than the causal relationships derived from randomized comparisons. This applies particularly when averages of patient characteristics in each study are used as covariates in the regression since the relationship with patient averages across studies may not be the same as the relationship for patients within studies (ecological bias) [28]. Furthermore a meta-regression approach will typically have lower power than an IPD meta-analysis.

IPD, both of outcomes and covariates, can alleviate some of the problems in meta-regression. In particular within-trial and between-trial relationships can be more clearly distinguished, and confounding by individual level covariates can be investigated. Nevertheless many of the problems remain, not least those related to data dredging, the main pitfall in reaching reliable conclusions from meta-regression. It can only be avoided by prespecification of covariates that will be investigated as potential sources of heterogeneity [28].

## 4 Evidence-based research

Evidence-based medicine is a hierarchy of evidence levels developed to standardize the interpretations of medical treatments. The RCTs, biomedical or health-related research studies in human beings that follow a pre-defined protocols, are considered the highest quality design as they allow to infer strong causal relationships. RCT evidence is now required for registration of drugs and medical devices in most of the developed nations.

In the drug development context, clinical trials are conducted in phases and the trials at each phase have a different purpose and help scientists answering different questions. Traditionally, Phase I trials are first-in-man studies to evaluate safety, determine a safe dosage range, and identify side effects of a specified treatment; Phase II trials are studies to select a promising treatment for further investigation; Phase III trials are large-scale controlled studies designed to demonstrate the efficacy of a novel treatment; and Phase IV trials, are post marketing studies to get additional information including the intervention's risks, benefits, and optimal use.

There has been considerable recent interest in statistical methods for clinical trials that combine the goals of early (learning) phases and later (confirmatory) phases, driven by the need of increasing efficiency and cost-effectiveness of the drug development process. A specific example is the seamless Phase II/III design addressing objectives normally achieved through separate Phase II and III trials [29]. Such a trial begins with groups of patients randomised to one or more competing experimental treatments and a control. One or more interim analyses are planned at which the various treatments are be evaluated. At these interim looks, less promising treatments will be dropped for futility, whilst those showing promise in terms of efficacy will continue to be evaluated in the later stages of the trial. The use of some more rapidly observable early endpoints in Phase II trials, suggested that a possibility could be to similarly base decision-making in the early stages of a seamless Phase II/III trial on a early endpoint.



Not all intervention programmes are candidates for these designs, particularly if complex treatment regimens are involved and a long follow-up time to assess the surrogate is needed [30].

Methods for the use of early endpoint data based on the group-sequential approach have been proposed in settings where the correlation between the endpoints can be assumed known or estimated from data on both endpoints from an interim analysis, or based on the combination test approach when no primary endpoint data are available at the interim analysis. In both approaches, it is a challenge to determine sample size for achieving the desired power and to carry out a valid final analysis combining data from both phases.

The use of an early endpoint at the interim analysis and of a primary endpoint at a later analysis on the same patients, leads to potential type I error inflation due to correlation between the two endpoints. The basic idea behind group sequential designs is to avoid excessive false conclusions by using much lower significance levels than the overall  $\alpha$  at each interim analysis.

In a classical design, the test statistic  $S$  (i.e. a  $t$ -test, a Chi-square test or a  $z$ -test depending on the response variable chosen as the trial endpoint), is used to derive the probability of rejection of the null or the alternative hypothesis. Such exercise is performed once, at the end of the study enrolment and outcome evaluation.

In a one-sided group sequential test, such exercise is repeated at each  $k$ -th interim analysis,  $k=1, \dots, K$ . In this case, the test statistics  $S_k$  that are appropriate for the type of response data being monitored are compared with boundary values  $l_k$  and  $u_k$ :

- if  $S_k > u_k$ , the trial will be stopped with the null hypothesis rejected in favour of the one-sided alternative;
- if  $S_k > l_k$ , the trial will be stopped and the null hypothesis will not be rejected;
- if  $l_k < S_k < u_k$  the trials continues to the  $(k+1)$ -th interim analysis.

Here  $l_1, u_1, \dots, l_K, u_K$  are constants with  $l_K < u_K$  for  $k=1, \dots, K-1$  and  $l_K = u_K$  in order to ensure a final decision. These stopping limits are chosen to control the type I error probability, i.e.,  $P(S_1 > u_1 \text{ or } \dots \text{ or } S_K > u_K) = \alpha$ . The nominal significance level at the  $k$ -th analysis is defined as the marginal probability  $\alpha_k = P(S_K > u_K)$  and should not be confused with the probability  $\pi_k$  of stopping at stage  $k$  and rejecting the null hypothesis,  $\pi_k = P(l_1 < S_1 < u_1, \dots, l_{k-1} < S_{k-1} < u_{k-1}, S_k > u_k)$ . Since  $\pi_1 + \dots + \pi_K = \alpha$ ,  $\pi_k$  is sometimes referred to as the error spent at stage  $k$ .

The values of  $l_k$  and  $u_k$  can be obtained via a recursive numerical integration technique first described by Armitage et al [31]. Further details are given by Jennison and Turnbull [32].

An alternative approach to analysing data at interim analyses, is the combination test approach proposed by Bauer and Köhne [33]. The origin of this procedure lies in Fisher combination test which combines the one-sided p-values  $p_1$  and  $p_2$  from the two separate stages of the trial through an appropriate function. The null hypothesis is rejected if  $p_1 p_2 < l_2 = \exp(-1/2 \chi_{4,\alpha}^2)$  where  $\chi_{4,\alpha}^2$  is the 100(1- $\alpha$ )-th percentile of a Chi-square distribution with four degrees of freedom. To stop the trial for futility, a lower bound for  $p_1$ ,  $\alpha_0$ , must be specified. To get an overall  $\alpha$ -level test, a value  $\alpha_1 > l_2$  has to be determined.

The application of the combination test can be summarized as follows:

- if  $p_1 > \alpha_0$ , the trial will be stopped and the null hypothesis will not be rejected (stopping for futility);
- if  $p_1 < \alpha_1$ , the trial will be stopped and the null hypothesis will be rejected;
- if  $\alpha_1 < p_1 < \alpha_0$  the trials continues to the second stage.

Alternatively, the independent test statistics from the different stages of the trial can be combined directly [34]. These two types of adaptive procedures have been compared by Wassmer [35].

## 4.1 Evidence-based nutrition

During the last decade, approaches to evidence-based medicine, have been adapted to nutrition science and policy. However, there are distinct differences between the evidence that can be obtained for the testing of drugs using RCTs and those needed for the development of nutrient requirements or dietary guidelines. Although RCTs present one approach toward understanding the efficacy of nutrient interventions, the innate complexities of nutrient actions and interactions cannot always be adequately addressed through any single research design [36].

The difference we focus on is between endpoints.

While drugs acts promptly and their endpoint can be measured over relatively short periods of time, nutrients effects tend to manifest themselves in small differences over long periods of time. This is the reason why the use of surrogate endpoints is particularly relevant for functional food research. Although the motivation for using seamless designs incorporating short-term and long-term endpoints may be shared by evidence-based medicine and evidence-based nutrition, the unavailability of the true endpoint even at later stages of the trial, makes such methods not completely fit to functional food research.

Our proposal is to adapt to the functional food context the method developed by Chow [37] for a two-stage seamless designs. In his work he proposed a test statistic for the final analysis, based on combined data from the learning phase and the confirmatory phase of a seamless Phase II/III trial, assuming an established linear relationship between the two different study endpoints. Similarly, under a relationship between the surrogate and the true endpoint, established in the surrogacy assessment, we derive design considerations, in terms of sample size and power of a test on the true endpoint based on its conditional variance.

## 4.2 Continuous data

Suppose the investigators are planning a single arm Phase II study to evaluate activity of a dietary intervention on a validated surrogate endpoint  $S$ .

Let us assume that  $S_j$  are independently and normally distributed random variables with mean  $\mu$  unknown and variance  $\xi^2$  known. The following null ( $H_0$ ) and alternative hypotheses ( $H_1$ ) are considered:

$$H_0 : \mu = \gamma_0 \quad \text{vs.} \quad H_1 : \mu = \gamma_1 \quad (\gamma_1 > \gamma_0)$$

The sample size  $n_{S1}$  determined such that the corresponding  $\alpha$ -level test would achieve a fixed  $(1-\beta)$  power is:

$$n_{S1} = \frac{(z_{1-\beta} - z_{\alpha/2})^2 \xi^2}{(\gamma_1 - \gamma_0)^2} \quad (14)$$

where  $z_{1-\beta}$  and  $z_{\alpha/2}$  are the quantiles  $1 - \beta$  and  $\alpha/2$ , respectively, of the standard normal distribution.

Suppose that  $S$  is a valid surrogate endpoint for the true endpoint  $T$  and they can be related by the following relationship (as in equation (3)):

$$T_j = \phi + \gamma S_j + \epsilon_j \quad (15)$$

We assume that this relationship is well-explored,  $\phi$  and  $\gamma$  are known, and  $\epsilon_j$  are zero-mean normally distributed error terms with variance  $\sigma^2$ . We recall that the assessment of the third Prentice's criterion for surrogacy requires the exploration of this relationship through a the test for parameter  $\gamma$ .

Even though  $T$  is unobservable, the investigators may be interested in linking a test on  $S$  with a test on  $T$  with the same power and  $\alpha$  level, both in terms of hypotheses specification and sample size.

Let us define a generic set of hypotheses for a one-sample test on the mean of  $T$ :

$$H_0 : \mu = \mu_0 \quad \text{vs.} \quad H_1 : \mu = \mu_1 \quad (\mu_1 > \mu_0)$$

By replacing  $\mu_1$  with the predicted value of  $T$  at  $S_j = \gamma_1$ ,  $\hat{\mu}_1$ , in the following equation :

$$\frac{\gamma_1 - \gamma_0}{\xi} = \frac{\mu_1 - \mu_0}{\sigma} \quad (16)$$

we get  $\mu_0 = \hat{\mu}_1 + \frac{(\gamma_0 - \gamma_1)\sigma}{\xi}$ .

Therefore, the sample size  $n_{T1}$ , as a function of the value of  $\mu_1$ , determined

such that the corresponding  $\alpha$ -level test would achieve the fixed  $(1-\beta)$  power is:

$$n_{T1} = \frac{(z_{1-\beta} - z_{\alpha/2})^2 \sigma^2}{\left[ \mu_1 - \hat{\mu}_1 + \frac{(\gamma_1 - \gamma_0)\sigma}{\xi} \right]^2} \quad (17)$$

that can be rewritten as:

$$n_{T1} = n_{S1} \frac{(\gamma_1 - \gamma_0)^2 \sigma^2}{[(\mu_1 - \hat{\mu}_1)\xi + (\gamma_1 - \gamma_0)\sigma]^2} \quad (18)$$

The same connection can be made between the sample size  $n_{S1}$  and the sample size for a Phase III trial with two balanced arms,  $A$  and  $B$ , with  $T$  as primary endpoint, say  $n_{T2}$ . In this case the set of hypotheses is:

$$H_0 : \mu_A - \mu_B = 0 \quad \text{vs.} \quad H_1 : \mu_A - \mu_B = \mu_1 - \mu_0 \quad (> 0)$$

Assuming that the variance  $\sigma^2$  is the same in both arms and recalling that  $n_{T2} = 4n_{T1}$  (with the same power and  $\alpha$  level),  $n_{T2}$  may be rewritten as:

$$n_{T2} = n_{S1} \frac{(\gamma_1 - \gamma_0)^2 4\sigma^2}{[(\mu_1 - \hat{\mu}_1)\xi + (\gamma_1 - \gamma_0)\sigma]^2} \quad (19)$$

Suppose the investigators are planning a two-arm Phase III study to evaluate efficacy of a dietary intervention on a validated surrogate endpoint  $S$ , with the same variance  $\xi^2$  in both arms with:

$$H_0 : \mu_A - \mu_B = 0 \quad \text{vs.} \quad H_1 : \mu_A - \mu_B = \gamma_1 - \gamma_0 \quad (> 0)$$

Directly from equation (18), it follows:

$$n_{T2} = n_{S2} \frac{(\gamma_1 - \gamma_0)^2 \sigma^2}{[(\mu_1 - \hat{\mu}_1)\xi + (\gamma_1 - \gamma_0)\sigma]^2} \quad (20)$$

These results are summarized in Table 4 and can be extended to the case of unknown variance by referring to a  $t$ -test rather than a  $z$ -test. Obviously, by setting  $\mu_1 = \hat{\mu}_1$ ,  $n_{T1} = n_{S1}$  and  $n_{T2} = n_{S2}$ . This means that the same sample size that provides a fixed power for an  $\alpha$ -level test on the difference of means  $\gamma_1 - \gamma_0$  on the surrogate, also provides the same power for an  $\alpha$ -level test on the difference  $(\gamma_1 - \gamma_0)\sigma/\xi$  on the true endpoint. The joint

consideration of these two sets of hypotheses, one on the surrogate and the other on the true endpoint, helps orienting the investigators and, hopefully, discourages studies on the surrogate that would allow to test only unrealistic effects on the true endpoint.

Surrogate\True	Phase II	Phase III
Phase II	$n_{T1} = n_{S1} \frac{(\gamma_1 - \gamma_0)^2 \sigma^2}{[(\mu_1 - \hat{\mu}_1)\xi + (\gamma_1 - \gamma_0)\sigma]^2}$	$n_{T2} = n_{S1} \frac{(\gamma_1 - \gamma_0)^2 4\sigma^2}{[(\mu_1 - \hat{\mu}_1)\xi + (\gamma_1 - \gamma_0)\sigma]^2}$
Phase III	-	$n_{T2} = n_{S2} \frac{(\gamma_1 - \gamma_0)^2 \sigma^2}{[(\mu_1 - \hat{\mu}_1)\xi + (\gamma_1 - \gamma_0)\sigma]^2}$

Table 4. Sample size of a single-arm Phase II ( $n_{T1}$ ) trial and two-arm Phase III ( $n_{T2}$ ) trial for the true endpoint as a function of the sample sizes for the surrogate endpoint under equation (13). Power and two-sided  $\alpha$ -level are the same for all study designs.

### 4.3 Validation of a prognostic model

In medical research, regression models for investigating patient outcome in relation to patient and disease characteristics as in (15) are termed prognostic models.

According to the definition given by Altman [38], a statistically validated prognostic model is one which passes all appropriate statistical checks, including goodness-of-fit on the original data and unbiased prediction on new data.

One common way of establishing how well a model might perform for further patients is data splitting or cross-validation. Here the original sample is split into two parts before the modelling begins. The model is derived on the first portion of the data (often called the training set) and then its ability to predict outcome is evaluated on the second or test data set. A variation is to carry out the modelling procedure on each portion of the data and to evaluate each model on the other portion.

An issue is how to split the data set. Although cross-validation is widely recommended, authors rarely consider what proportion of patients should be in the test and training sets (or fail to justify any recommendation).

Random splitting must lead to data sets that are the same other than for chance variation and is thus a weak procedure. Furthermore, estimates of predictive accuracy from data-splitting procedures, though unbiased, tend to be imprecise (see Efron and Tibshirani [39]).

A tougher test is to split the data in a non-random way. For example, we might take groups of patients seen in different time periods. Rather different, and better, approaches are to use bootstrapping or leave-one out cross-validation. From these analyses shrinkage factors can be estimated and applied to the regression coefficients to counter overoptimism (see Harrell [40]).

In the case of univariable ordinary least squares regression we can define the ordinary predictor for any value  $s$  of  $S$  as  $\mu = \bar{T} + (\bar{S} - s)\hat{\gamma}$ , where  $\bar{T}$  and  $\bar{S}$  are the sample mean of  $T$  and  $S$ , respectively.

Van Houwelingen and Le Cessie [41] suggest shrinking this ordinary predictor in dependence on a shrinkage factor  $c$ . The resulting predictor is then defined by  $\mu^S = \bar{T} + (\bar{S} - s)c\hat{\gamma}$ . Furthermore they suggest to estimate the shrinkage factor  $c$  by cross-validation which is performed in the following way: for each individual  $j$  of the sample the estimate  $\hat{\gamma}_{-j}$  based on all individuals except  $j$  is computed. Next for each individual the linear predictor  $\eta_j = \hat{\phi} + s_j\hat{\gamma}_{-j}$  is computed. Then a generalized linear model with  $T_j$  and  $\eta_j$  as dependent and independent variable, respectively, is fitted to the observations. The regression coefficient  $\hat{c}$  obtained is then taken as the shrinkage factor, resulting in a new predictor  $\mu^{\hat{S}}$ , preferable to the ordinary predictor with respect to the expected average prediction error.

As we would expect to predict a variation on the true endpoint for future patients consequent upon a variation on the surrogate, attention to the issue of overoptimistic prediction in (15) should be paid.

## 5 Surrogate Endpoint for Cardiovascular Risk Reduction: a case-study

CVD, a major cause of death in Western populations and a constantly growing cause of morbidity and mortality worldwide, can be prevented by lifestyle changes, one of which is diet [42].

Numerous potential surrogate endpoints of CVD are being evaluated as the pathophysiology of heart disease is becoming better understood. Functional foods marketed with the claim of reduction of heart disease risk often focus on these surrogates.

High cholesterol concentration is a well-established risk factor for CVD as it can lead to atherosclerotic plaque formation, which can lead to a narrowing of the coronary arteries. Atherosclerotic plaques can rupture and lead to a heart attack or a stroke. Primary prevention trials using cholesterol-lowering drugs and dietary interventions have shown that lowering blood cholesterol can reduce the risk of myocardial infarction and death from CHD. Elevated blood cholesterol concentration has been associated with increased risk of CVD in several observational studies [43].

For example, the FDA used blood total cholesterol concentration as a surrogate endpoint for CVD risk to substantiate several authorized health claims: 1) saturated fat and cholesterol and increased risk of CHD, 2) fruits, vegetables, and grain products that contain fiber (particularly soluble fiber) and reduced risk of CHD, 3) soluble fiber from certain foods and reduced risk of CHD, 4) soy protein and reduced risk of CHD, and 5) stanols/sterols and reduced risk of CHD. In addition, three health claims based on credible scientific evidence, the so-called qualified health claims, were issued based on studies using blood total cholesterol as a surrogate endpoint. These claims include the following: 1) unsaturated fatty acids from canola oil and reduced risk of CHD, 2) monounsaturated fatty acids from olive oil and reduced risk of CHD, and 3) corn oil and products containing corn oil and reduced risk



of heart disease.

## 5.1 Methods

### *Surrogacy assessment.*

The meta-analyses by Gould et al. [44-46] contributed to the validation of total cholesterol as a surrogate endpoint for CVD.

Using the 27 trials included in [45] that regard a unifactorial primary or secondary intervention classified as “Diet/Other” or “Statin”, we verified Prentice criteria for surrogacy under a random-effect metanalysis perspective. The CHD mortality log odds ratio (CHDlogOR) is the true endpoint and the net improvement in percentage cholesterol reduction (%ChRed) is the surrogate endpoint.

The within-study variance of %ChRed was not reported in [45], therefore we used an approximation to verify the first criterion, by calculating the weighted mean of %ChRed using the same inverse variance weights for CHDlogOR.

The other criteria were verified through random-effect meta-regression analyses, assuming a normal distribution for the residuals (as in (13)) and different predictors (intercept only, average within-study %ChRed, and average within-study %ChRed and treatment, respectively). REML and empirical Bayes estimates of  $\tau^2$  were considered.

The data are given in Table 5. The odds ratio of CHD is the summary of the results in each trial. Each odds ratio is estimated as the cross-product of cell counts in the corresponding 2x2 contingency table, with the variance of the log-odds ratio equal to the sum of the reciprocal cell counts, as usual. In the trials with no events in one group, 0.5 is added to each cell for these calculations.

On the basis of the investigated relation between CHDlogOR and %ChRed we make sample size considerations for a test on means between two groups.

Intervention	%ChRed	CHD deaths/ $N_I$	CHD deaths/ $N_C$
Diet/Other	9	32/1906	44/1900
	9.8	19/1149	31/1129
	12.7	41/424	50/422
	23.3	33/421	41/417
	14	13/77	23/143
	9.9	238/1119	632/2789
	4	97/1018	97/1015
	4.3	37/221	24/237
	8.3	17/123	20/129
	8.8	8/54	1/26
	13.5	25/199	25/194
	13.9	37/206	50/206
	30.3	NA	NA
	19.1	NA	NA
	12.2	1/26	3/28
	23.3	0/24	3/28
16	NA	NA	
22	NA	NA	
Statin	20	41/3302	61/3293
	26	111/2221	189/2223
	20	96/2081	119/2078
	12.1	2/76	4/75
	20	0/460	6/459
	31	NA	NA
	20	2/168	1/166
	22	4/193	4/188
	20	10/955	12/936

Table 5. Trials included in [45] being "Diet/Other" or "Statin" the interventions.  $N_I$ : sample size of the intervention arm,  $N_C$ : sample size of the control arm, NA: data not available.

*Simulation study.*

The scenario chosen for simulation aims to represent the investigated relation between CHDlogOR and %ChRed where an hypothetical shrinkage factor of 0.8 (with an assigned between-study distribution) is applied to correct for overestimation of the conditional expectation of CHDlogOR.

The individual value of CHDlogOR ( $T_i$ ) as a function of %ChRed ( $S_i$ ) was generated for 50 studies according to the relation  $T_i = \gamma S_i c_i + \epsilon_i$ , where  $S_i$  and  $\epsilon_i$  were from a Normal with mean equal to 14 and variance  $\xi^2 = 49$  and a zero-mean Normal with two different choices for the variance  $\sigma^2$ : 0.04 and 0.64, respectively. Two different values of the regression coefficient  $\gamma$  were chosen, namely -0.017 and -0.17, and three different shrinkage ( $c_i$ ) mechanisms were considered:  $c_i$  generated according to a Gamma with mean 0.8 and variance  $\sigma_S^2 = 0.01$ ,  $\sigma_S^2 = 0.04$  or  $\sigma_S^2 = 0.1$ , respectively. This means that a factor of 0.8 is needed to correct for overestimation of the conditional expectation of CHDlogOR and the conditional variance, now depending on the value taken by %ChRed, is increased.

The sample size to achieve a 80% or a 90% power for a two-sided ( $\alpha = 5\%$ ) test on the difference of means ( $\mu_A - \mu_B$ ) of %ChRed was calculated according to formulas given in subsection 4.1, assuming  $\xi^2 = 49$  and under different alternative hypotheses:  $\mu_A - \mu_B = 1$ ,  $\mu_A - \mu_B = 1.5$ ,  $\mu_A - \mu_B = 2$  and  $\mu_A - \mu_B = 5$ . On the basis of the surrogacy results, corresponding hypotheses formulation for a test on the difference of means of CHDlogOR were derived (see Table 6).

Finally, the Monte Carlo experiment was conducted by estimating the power of a test with effect size and sample size as in Table 6 under known (heteroschedastic) variance  $((\%ChRed \cdot \gamma)^2 \sigma_S^2 + \sigma^2)$  due to shrinkage for each depicted scenario, each with 1000 runs, using the default random number generating functions in R software. Monte Carlo statistics such as the mean power and the mean square error (MSE), which equals the mean of the squared difference between estimated and true power in each simulation, were calculated.

%ChRed	CHDlogOR ( $\sigma^2=0.04$ )	CHDlogOR ( $\sigma^2=0.64$ )	$n_{S_2}^{80\%}$	$n_{S_2}^{90\%}$
1	0.029 (OR=1.03)	0.114 (OR=1.12)	1542	2062
1.5	0.043 (OR=1.04)	0.171 (OR=1.19)	686	918
2	0.057 (OR=1.06)	0.229 (OR=1.26)	388	518
5	0.143 (OR=1.15)	0.571 (OR=1.77)	64	86

Table 6. Sample size ( $n_{S_2}^{power}$ ) of a two-arm Phase III trial testing the difference of means for % Net cholesterol reduction (%ChRed) with  $\xi^2=49$  and corresponding hypotheses formulation for a Phase III trial for mean CHDlogOR with the same sample size and known variance  $\sigma^2=0.04$  or  $\sigma^2=0.64$ . Power=0.8 or 0.9 and two-sided  $\alpha=0.05$ . OR: Odds Ratio.

## 5.2 Results

### *Surrogacy assessment.*

The estimate of the mean %ChRed is 10.7 with 95% Confidence Interval (95%CI) equal to 7.6-13.8 and 21.9 (95%CI: 19.1-24.7) for “Diet/Other” and “Statin”, respectively (first criterion verified). The estimate of the mean CHDlogOR is -0.115 (95%CI: -0.227; -0.003) and -0.41 (95%CI: -0.570; -0.250) for “Diet/Other” and “Statin”, respectively (second criterion verified). For one unit increase in %ChRed, the estimated mean of CHDlogOR is -0.026 (95%CI: -0.039; -0.013) (third criterion verified) and the intercept is 0.159 (95%CI: -0.047; 0.365). The trend estimate (model without intercept) is -0.017 (95%CI: -0.023; -0.011) as shown in Figure 2.

After adjustment for %ChRed, the treatment effect (“Statin” vs. “Diet/Other”) on CHDlogOR is 0.09 (95%CI: -0.252 ; 0.440) (Prentice criterion verified).

The fact that a common slope applies for both interventions implies that there is no evidence to conclude that CHD mortality risk reduction is anything other than proportional to net reduction in cholesterol.

The REML and empirical Bayes estimates of  $\tau^2$  were equal to zero for all models therefore the results of the random-effects meta-regression reduce to those of the fixed-effect model.




Figure 2: Observed CHDlogOR and predicted regression line relating CHDlogOR and %ChRed. The area of each circle is inversely proportional to the variance of the CHDlogOR.

*Simulation study.*

The results of the simulation study for power=80% are shown in Tables 7a and 7b and those for power=90% are shown in Tables 8a and 8b.

When the effect of %ChRed is small ( $\gamma=-0.017$ ) the effect of shrinkage on power is negligible, regardless of its variance  $\sigma_S^2$ .

For increasing values of  $\gamma$ , a test relying on  $n_{S2}$  is underpowered. The higher the hypothesized difference in means of CHDlogOR and the shrinkage variance  $\sigma_S^2$ , the larger the extent of underpowering. This effect is inversely related to  $\sigma^2$ . For example, given an estimated reduction of CHDlogOR of -0.17 for one unit increase in %ChRed and a shrinkage with  $\sigma_S^2 = 0.1$ , the power of a test to detect a difference of means of CHDlogOR equal to 0.143 (corresponding to  $\sigma^2 = 0.04$ ) on 64 subjects (32 per arm), would be reduced from 80% to 39% (Table 7a). This reduction would be smaller, from 80% to 76%, for a larger variance  $\sigma^2 = 0.64$  (Table 7b).

Shrinkage	Effect ( $\gamma$ )	%ChRed	CHDlogOR	Power	MSE
Gamma $\sigma_S^2 = 0.01$	-0.017	1	0.029	0.800	0.025
		1.5	0.043	0.799	0.024
		2	0.057	0.801	0.024
		5	0.143	0.801	0.025
	-0.17	1	0.029	0.797	0.025
		1.5	0.043	0.793	0.026
		2	0.057	0.790	0.027
		5	0.143	0.736	0.072
Gamma $\sigma_S^2 = 0.04$	-0.017	1	0.029	0.800	0.025
		1.5	0.043	0.799	0.024
		2	0.057	0.801	0.025
		5	0.143	0.799	0.024
	-0.17	1	0.029	0.789	0.028
		1.5	0.043	0.774	0.037
		2	0.057	0.757	0.052
		5	0.143	0.573	0.230
Gamma $\sigma_S^2 = 0.1$	-0.017	1	0.029	0.800	0.025
		1.5	0.043	0.799	0.024
		2	0.057	0.800	0.024
		5	0.143	0.796	0.026
	-0.17	1	0.029	0.772	0.039
		1.5	0.043	0.738	0.069
		2	0.057	0.696	0.108
		5	0.143	0.390	0.410

Table 7a. Power of a two-sided ( $\alpha = 5\%$ ) test on CHDlogOR with heteroschedastic variance due to shrinkage and sample size equal to the one of a 80% powered test on CHDlogOR with variance  $\sigma^2=0.04$ . MSE: mean square error.

Shrinkage	Effect ( $\gamma$ )	%ChRed	CHDlogOR	Power	MSE
Gamma $\sigma_S^2 = 0.01$	-0.017	1	0.114	0.801	0.025
		1.5	0.171	0.799	0.024
		2	0.229	0.801	0.025
		5	0.571	0.801	0.025
	-0.17	1	0.114	0.800	0.025
		1.5	0.171	0.800	0.024
		2	0.229	0.800	0.027
		5	0.571	0.799	0.072
Gamma $\sigma_S^2 = 0.04$	-0.017	1	0.114	0.800	0.025
		1.5	0.171	0.800	0.024
		2	0.229	0.801	0.025
		5	0.571	0.802	0.024
	-0.17	1	0.114	0.800	0.025
		1.5	0.171	0.799	0.025
		2	0.229	0.798	0.026
		5	0.571	0.786	0.030
Gamma $\sigma_S^2 = 0.1$	-0.017	1	0.114	0.800	0.025
		1.5	0.171	0.800	0.025
		2	0.229	0.803	0.025
		5	0.517	0.800	0.026
	-0.17	1	0.114	0.799	0.025
		1.5	0.171	0.796	0.025
		2	0.229	0.794	0.026
		5	0.571	0.760	0.049

Table 7b. Power of a two-sided ( $\alpha = 5\%$ ) test on CHDlogOR with heteroschedastic variance due to shrinkage and sample size equal to the one of a 80% powered test on CHDlogOR with variance  $\sigma^2=0.64$ . MSE: mean square error.

Shrinkage	Effect ( $\gamma$ )	%ChRed	CHDlogOR	Power	MSE
Gamma $\sigma_S^2 = 0.01$	-0.017	1	0.029	0.900	0.018
		1.5	0.043	0.900	0.018
		2	0.057	0.900	0.018
		5	0.143	0.905	0.019
	-0.17	1	0.029	0.898	0.018
		1.5	0.043	0.895	0.019
		2	0.057	0.891	0.021
		5	0.143	0.854	0.051
Gamma $\sigma_S^2 = 0.04$	-0.017	1	0.029	0.900	0.018
		1.5	0.043	0.900	0.018
		2	0.057	0.900	0.101
		5	0.143	0.903	0.018
	-0.17	1	0.029	0.892	0.020
		1.5	0.043	0.882	0.027
		2	0.057	0.867	0.039
		5	0.143	0.704	0.198
Gamma $\sigma_S^2 = 0.1$	-0.017	1	0.029	0.900	0.018
		1.5	0.043	0.900	0.018
		2	0.057	0.899	0.102
		5	0.143	0.900	0.018
	-0.17	1	0.029	0.880	0.028
		1.5	0.043	0.853	0.052
		2	0.057	0.816	0.088
		5	0.143	0.500	0.401

Table 8a. Power of a two-sided ( $\alpha = 5\%$ ) test on CHDlogOR with heteroschedastic variance due to shrinkage and sample size equal to the one of a 90% powered test on CHDlogOR with variance  $\sigma^2=0.04$ . MSE: mean square error.



Shrinkage	Effect ( $\gamma$ )	%ChRed	CHDlogOR	Power	MSE
Gamma $\sigma_S^2 = 0.01$	-0.017	1	0.114	0.900	0.019
		1.5	0.171	0.900	0.018
		2	0.229	0.901	0.018
		5	0.571	0.905	0.018
	-0.17	1	0.114	0.900	0.019
		1.5	0.171	0.900	0.018
		2	0.229	0.900	0.018
		5	0.571	0.902	0.017
Gamma $\sigma_S^2 = 0.04$	-0.017	1	0.114	0.900	0.019
		1.5	0.171	0.900	0.018
		2	0.229	0.901	0.018
		5	0.571	0.905	0.018
	-0.17	1	0.114	0.899	0.019
		1.5	0.171	0.899	0.018
		2	0.229	0.899	0.018
		5	0.571	0.893	0.020
Gamma $\sigma_S^2 = 0.1$	-0.017	1	0.114	0.900	0.019
		1.5	0.171	0.900	0.018
		2	0.229	0.900	0.018
		5	0.517	0.905	0.018
	-0.17	1	0.114	0.899	0.019
		1.5	0.171	0.897	0.018
		2	0.229	0.896	0.019
		5	0.571	0.875	0.032

Table 8b. Power of a two-sided ( $\alpha = 5\%$ ) test on CHDlogOR with heteroschedastic variance due to shrinkage and sample size equal to the one of a 90% powered test on CHDlogOR with variance  $\sigma^2=0.64$ . MSE: mean square error.

### 5.3 Discussion

The joint consideration of the two sets of hypotheses, one on the surrogate and the other on the true endpoint, helps orienting the investigators and, hopefully, discourages RCTs on the surrogate that would allow to test only unrealistic effects on the true endpoint.

On the basis of the surrogacy results in the case study, if a study on an intervention involving functional foods, with cholesterol reduction as the primary endpoint, were designed, it would probably be powered to detect small net improvements in percentage cholesterol reduction. Actually, this sample size would provide the same power to a test on a likely CHD mortality reduction.

A key issue is the accuracy in deriving the relation between the surrogate and the true endpoint. As shown in the simulation study, under a model that incorporates an among-study variation, the estimated power could be seriously reduced compared to that expected under a mis-specified relation that ignores such a variation.

If we interpret this variation as the between-study variation  $\tau^2$ , incorporated in the formulation of a random-effect model, the issue of model-fitting we are focusing on, relates to the choice of a random-effect rather than a fixed-effect model. In the case study, the estimate of  $\tau^2$  is zero therefore the results of the random-effects meta-regression reduce to those of the fixed-effect model.

It is well recognized that  $\tau^2$  is a key parameter in a random-effect meta-analysis and provides probably the most appropriate measure of the extent of heterogeneity. It is conventional to assume a normal distribution for the underlying effects in a random-effect distribution but it is important to recognize that the suitability of this assumption should be assessed. If the effect were not normally distributed (i.e. Gamma distributed as in the simulations) flexible random effect approaches, avoiding a specific model assumption, could be adopted [22]. Departures from linearity in the relation between endpoints and the introduction of non-normal random effect distributions in meta-regression remain interesting topics requiring further investigation.

## 6 Conclusions

Functional foods with their specific health effects could, in the future, indicate a new mode of thinking about the relationships between food and health in everyday life. Surrogate endpoints have great potential for use in functional food research but their adoption should rely on the achievement of biological and statistical requirements for validation.

Incomplete knowledge of the biological role of surrogates on mechanisms by which food components positively affect health could lead to surrogate endpoint failure for several reasons [21]:  $S$  may not be in the causal pathway of the health condition of interest; of several causal pathways, the dietary intervention affects only the pathway mediated through  $S$ ; the dietary intervention acts independently of the health process of interest; and  $S$  is measured with error and its effect does not meaningfully alter  $T$ .

While validation criteria are still an area of intense statistical research, the common basis is that the surrogate must be predictive of the true endpoint and the effect of the intervention on the surrogate must be sufficiently correlated with the effect on the true endpoint.

This study indicates that, besides being important per se, the surrogacy assessment could provide useful information to link the inference on the surrogate with the inference that would be made on the true endpoint.

As acknowledged in [13], on the one hand it is important to conduct the investigations necessary to evaluate potential surrogates that include information on  $Z$ ,  $S$ , and  $T$  for study participants, and on the other hand, it is obvious to recognize that the large, long, expensive studies required to fully evaluate potential surrogates are exactly the studies that surrogates were designed to replace. This limitation of surrogacy needs not be regarded as a cause for pessimism in functional food research. It reminds for continuous research on the relationships between food components and an improved state of health and/or a reduced risk of a disease, and affirms the continued importance of either large clinical trials or observational epidemiologic studies

with true endpoints as well. Although surrogacy assessments on IPD represent the gold standard, at present, great efforts are needed to obtain IPD. Issues of ownership and access to data for use in meta-analyses need to be addressed, and we hope initiatives will be set in place to make meta-analyses using IPD easier in the future.

## 7 Appendix

The present work will be presented at the ILSI Europe Symposium on “Health Benefits of Foods - From Emerging Science to Innovative Products”, Prague, Czech Republic, 05/10/2011 - 07/10/2011.

An article from the present work has been submitted for publication to the peer-reviewed scientific journal *International Journal of Food Sciences and Nutrition*.



































## References

- [1] Riezzo G, Chiloiro M, Russo F: Functional foods: salient features and clinical applications. *Curr Drug Targets Immune Endocr Metabol Disord* 2005;5:331-337.
- [2] Scientific concepts of functional foods in Europe. Consensus document. *Br J Nutr* 1999;81 Suppl 1:S1-27.
- [3] EC Regulation No 1924/2006: EC Regulation No 1924/2006 on nutrition and health claims made on foods. *Official Journal of the European Union* L12/3 - L12/18.
- [4] Buttriss JL, Benelam B: Nutrition and health claims: the role of food composition data. *Eur J Clin Nutr*;64 Suppl 3:S8-13.
- [5] Lupton JR: Scientific substantiation of claims in the USA: focus on functional foods. *Eur J Nutr* 2009;48 Suppl 1:S27-31.
- [6] Howlett J: Functional Foods from science to health and claims. International Life Science Institute (ILSI Europe), 2008.
- [7] ILSI Europe: Beyond PASSCLAIM - Guidance to substantiate health claims on foods. International Life Science Institute (ILSI Europe), 2009.
- [8] AbuMweis SS, Jew S, Jones PJ: Optimizing clinical trial design for assessing the efficacy of functional foods. *Nutr Rev*;68:485-499.
- [9] Heaney RP: Nutrition, chronic disease, and the problem of proof. *Am J Clin Nutr* 2006;84:471-472.
- [10] Buyse M, Sargent DJ, Grothey A, Matheson A, de Gramont A: Biomarkers and surrogate end points—the challenge of statistical validation. *Nat Rev Clin Oncol*;7:309-317.
- [11] Lin DY, Zeng D: On the relative efficiency of using summary statistics versus individual-level data in meta-analysis. *Biometrika* 2010;97:321-332.

- [12] Prentice RL: Surrogate endpoints in clinical trials: definition and operational criteria. *Stat Med* 1989;8:431-440.
- [13] Burzykowski T, Molenberghs G, Buyse M (eds): *The Evaluation of Surrogate Endpoint*. New York, Springer, 2005.
- [14] Freedman LS, Graubard BI, Schatzkin A: Statistical validation of intermediate endpoints for chronic diseases. *Stat Med* 1992;11:167-178.
- [15] Herson J: Fieller's Theorem Versus the Delta Method for Significance Intervals for Ratios. *Journal of Statistical Computing and Simulation* 1975;3:265-274.
- [16] Buyse M, Molenberghs G: Criteria for the validation of surrogate endpoints in randomized experiments. *Biometrics* 1998;54:1014-1029.
- [17] Buyse M: Use of meta-analysis for the validation of surrogate endpoints and biomarkers in cancer trials. *Cancer J* 2009;15:421-425.
- [18] Heitjan DF, Rubin D: Ignorability and coarse data. *Annals of Statistics* 1991;19:2244-2253.
- [19] Leung DH-Y: Statistical methods for clinical studies in the presence of surrogate end points. *Journal of the Royal Statistical Society. Series A.* 2001;164:485-503.
- [20] Robins JM, Greenland S: Identifiability and exchangeability for direct and indirect effects. *Epidemiology* 1992;3:143-155.
- [21] Lasserre MN: The Biomarker-Surrogacy Evaluation Schema: a review of the biomarker-surrogate literature and a proposal for a criterion-based, quantitative, multidimensional hierarchical levels of evidence schema for evaluating the status of biomarkers as surrogate endpoints. *Stat Methods Med Res* 2008;17:303-340.
- [22] Sutton AJ, Higgins JP: Recent developments in meta-analysis. *Stat Med* 2008;27:625-650.

- [23] Cochran WG: The combination of estimates from different experiments. *Biometrics* 1954;10:101-129.
- [24] Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. *BMJ* 2003;327:557-560.
- [25] Thompson SG, Sharp SJ: Explaining heterogeneity in meta-analysis: a comparison of methods. *Stat Med* 1999;18:2693-2708.
- [26] Greenland S, Longnecker MP: Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. *Am J Epidemiol* 1992;135:1301-1309.
- [27] Shi JQ, Copas JB: Meta-analysis for trend estimation. *Stat Med* 2004;23:3-19; discussion 159-162.
- [28] Thompson SG, Higgins JP: How should meta-regression analyses be undertaken and interpreted? *Stat Med* 2002;21:1559-1573.
- [29] Stallard N, Todd S: Seamless phase II/III designs. *Stat Methods Med Res.*
- [30] Orloff J, Douglas F, Pinheiro J, Levinson S, Branson M, Chaturvedi P, Ette E, Gallo P, Hirsch G, Mehta C, Patel N, Sabir S, Springs S, Stanski D, Evers MR, Fleming E, Singh N, Tramontin T, Golub H: The future of drug development: advancing clinical trial design. *Nat Rev Drug Discov* 2009;8:949-957.
- [31] Armitage P, McPherson K, Rowe BC: Repeated significance tests on accumulating data. *J R Stat Soc Ser A* 1969;132:235-244.
- [32] Jennison C, Turnbull BW: *Group Sequential Methods with Applications to Clinical Trials*. New York, Chapman & Hall/CRC, 2000.
- [33] Bauer P, Köhne K: Evaluation of experiments with adaptive interim analyses *Biometrics* 1994;51:1029-1041.

- [34] Proschan MA, Hunsberger SA: Designed extension of studies based on conditional power. *Biometrics* 1995;51:1315-1324.
- [35] Wassmer G: A comparison of two methods for adaptive interim analyses in clinical trials. *Biometrics* 1998;54:831-838.
- [36] Blumberg J, Heaney RP, Huncharek M, Scholl T, Stampfer M, Vieth R, Weaver CM, Zeisel SH: Evidence-based criteria in the nutritional context. *Nutr Rev*;68:478-484.
- [37] Chow SC, Lu Q, Tse SK: Statistical analysis for two-stage seamless design with different study endpoints. *J Biopharm Stat* 2007;17:1163-1176.
- [38] Altman DG, Royston P: What do we mean by validating a prognostic model? *Stat Med* 2000;19:453-473.
- [39] Efron T, Tibshirani R (eds): *An introduction to the bootstrap*. London, Chapman & Hall, 1993.
- [40] Harrell FE, Jr.: *Regression Modeling Strategies*. New York, Springer, 2001.
- [41] Van Houwelingen JC, Le Cessie S: Predictive value of statistical models. *Stat Med* 1990;9:1303-1325.
- [42] Sirtori CR, Galli C, Anderson JW, Sirtori E, Arnoldi A: Functional foods for dyslipidaemia and cardiovascular risk prevention. *Nutr Res Rev* 2009;22:244-261.
- [43] Rasnake CM, Trumbo PR, Heinonen TM: Surrogate endpoints and emerging surrogate endpoints for risk reduction of cardiovascular disease. *Nutr Rev* 2008;66:76-81.
- [44] Gould AL, Davies GM, Alemao E, Yin DD, Cook JR: Cholesterol reduction yields clinical benefits: meta-analysis including recent trials. *Clin Ther* 2007;29:778-794.



- [45] Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD: Cholesterol reduction yields clinical benefit. A new look at old data. *Circulation* 1995;91:2274-2282.
- [46] Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD: Cholesterol reduction yields clinical benefit: impact of statin trials. *Circulation* 1998;97:946-952.